We are live on ! Find out more
OVID icon

Ovid Therapeutics
OVID

50 hedge funds and large institutions have $21.7M invested in Ovid Therapeutics in 2019 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 23 increasing their positions, 8 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

188% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 8

50% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 6

31% more capital invested

Capital invested by funds: $16.5M → $21.7M (+$5.2M)

6% more funds holding

Funds holding: 47 → 50 (+3)

4.03% more ownership

Funds ownership: 27.73% → 31.77% (+4%)

Holders
50
Holders Change
+3
Holders Change %
+6.38%
% of All Funds
1.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
23
Reduced
8
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$8.24M
2
GPCM
Granite Point Capital Management
Massachusetts
+$1.04M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$905K
4
Renaissance Technologies
Renaissance Technologies
New York
+$771K
5
Wells Fargo
Wells Fargo
California
+$768K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$1.87M
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$191K
3
JP Morgan Chase
JP Morgan Chase
New York
-$101K
4
Millennium Management
Millennium Management
New York
-$54K
5
SG Americas Securities
SG Americas Securities
New York
-$46K
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$5.83M +$8.24M +3,293,000 New
AC
2
Armistice Capital
New York
$3.15M +$450K +180,000 +11%
CI
3
Cowen Inc
New York
$1.95M +$625K +250,000 +29%
RG
4
Redmile Group
California
$1.3M – – –
BlackRock
5
BlackRock
New York
$1.18M -$1.87M -747,796 -53%
Vanguard Group
6
Vanguard Group
Pennsylvania
$1.16M +$905K +361,864 +124%
TCM
7
Tekla Capital Management
Massachusetts
$880K – – –
GPCM
8
Granite Point Capital Management
Massachusetts
$740K +$1.04M +417,857 New
Renaissance Technologies
9
Renaissance Technologies
New York
$643K +$771K +308,117 +559%
Wells Fargo
10
Wells Fargo
California
$556K +$768K +307,087 +4,451%
Deutsche Bank
11
Deutsche Bank
Germany
$454K +$513K +205,230 +394%
AC
12
AWH Capital
Texas
$407K +$575K +230,000 New
Alyeska Investment Group
13
Alyeska Investment Group
Illinois
$398K +$563K +225,000 New
Geode Capital Management
14
Geode Capital Management
Massachusetts
$390K +$312K +124,823 +130%
Northern Trust
15
Northern Trust
Illinois
$336K +$126K +50,481 +36%
State Street
16
State Street
Massachusetts
$333K +$45.3K +18,100 +11%
Acadian Asset Management
17
Acadian Asset Management
Massachusetts
$272K +$314K +125,690 +446%
Morgan Stanley
18
Morgan Stanley
New York
$224K +$218K +87,238 +226%
Charles Schwab
19
Charles Schwab
California
$179K +$105K +42,127 +72%
FC
20
Fairpointe Capital
Illinois
$179K +$150K +60,000 +146%
JP Morgan Chase
21
JP Morgan Chase
New York
$167K -$101K -40,236 -30%
Dimensional Fund Advisors
22
Dimensional Fund Advisors
Texas
$161K +$8.61K +3,444 +4%
BCM
23
Bridgeway Capital Management
Texas
$149K -$35K -14,000 -14%
OAM
24
Oxford Asset Management
United Kingdom
$108K +$94K +37,599 +160%
Two Sigma Investments
25
Two Sigma Investments
New York
$75K -$12.3K -4,903 -10%
1
2 3

OVID Hedge Fund Activity: Q1 2019 in Review

50 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q1 2019, worth a combined $21.7M — up 31% from $16.5M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new OVID positions and 6 closed out — a net gain of 3 holders — while 23 added to existing stakes and 8 trimmed.

The largest buyer was BVF Inc, opening a new position worth an estimated $8.24M. The largest seller was BlackRock, cutting an estimated $1.87M.

  • 50 institutional investors held Ovid Therapeutics (OVID) as of Q1 2019, up from 47 in Q4 2018.
  • Funds reported $21.7M of Ovid Therapeutics stock for Q1 2019, up 31% quarter-over-quarter.
  • 9 funds opened new Ovid Therapeutics positions in Q1 2019 and 6 closed out, a net change of +3 holders.
  • The largest Ovid Therapeutics buyer in Q1 2019 was BVF Inc, an estimated $8.24M added.
  • The largest Ovid Therapeutics seller in Q1 2019 was BlackRock, an estimated $1.87M sold.

Based on aggregated 13F filings for Q1 2019.